Beam Therapeutics (BEAM) to Release Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) will likely be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Beam Therapeutics to post earnings of ($1.13) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 7:00 AM ET.

Beam Therapeutics Price Performance

Shares of Beam Therapeutics stock opened at $27.92 on Tuesday. The stock has a market cap of $2.83 billion, a PE ratio of -6.30 and a beta of 2.12. The firm has a fifty day moving average price of $28.57 and a 200 day moving average price of $24.56. Beam Therapeutics has a 1 year low of $13.52 and a 1 year high of $36.44.

Insiders Place Their Bets

In other news, insider Christine Bellon sold 18,629 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $34.61, for a total value of $644,749.69. Following the completion of the sale, the insider owned 97,038 shares of the company’s stock, valued at $3,358,485.18. This represents a 16.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its stake in Beam Therapeutics by 12.9% during the fourth quarter. ARK Investment Management LLC now owns 12,467,189 shares of the company’s stock worth $345,590,000 after acquiring an additional 1,428,355 shares during the last quarter. State Street Corp lifted its stake in shares of Beam Therapeutics by 30.4% in the 4th quarter. State Street Corp now owns 5,228,529 shares of the company’s stock valued at $144,935,000 after purchasing an additional 1,219,871 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Beam Therapeutics by 237.5% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock valued at $40,419,000 after purchasing an additional 1,171,977 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Beam Therapeutics during the 4th quarter worth about $26,218,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Beam Therapeutics during the 2nd quarter worth about $10,101,000. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Sanford C. Bernstein increased their price target on shares of Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Evercore started coverage on Beam Therapeutics in a research note on Monday, November 24th. They issued an “outperform” rating and a $35.00 price objective for the company. Tudor Pickering set a $41.00 target price on shares of Beam Therapeutics in a report on Wednesday, January 21st. Benchmark reiterated a “speculative buy” rating on shares of Beam Therapeutics in a research report on Monday, November 17th. Finally, UBS Group started coverage on shares of Beam Therapeutics in a research report on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.80.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.